Takeda looks to China to support future growth

Takeda Pharmaceutical (TYO: 4502) chief executive Christophe Weber says his company will look to China for future growth in the wake of his firm’s  mega-takeover of rare disease specialist Shire (LSE: SHP).

In an interview with Bloomberg, Mr Weber said there was “no reason in the long term China shouldn’t be our second-biggest business in the world.”

He added that the firm’s objective was to launch new products in the country “at the same tempo as all of our markets, especially Europe and US.”